Joint Symposium 3
Neuroimaging Committee / EAN
Monday, October 21, 08:00 - 09:30

Session Title:
Image-Guided Anti-Amyloid Treatment in Alzheimer's Disease

Chairpersons:
Nelleke Tolboom (Utrecht, Netherlands)
Roland Wiest (Bern, Switzerland)

Programme:

08:00 - 08:30   **Gil Rabinovici** (San Francisco, USA): Anti-Amyloid Drugs to Treat Alzheimer's Disease

08:30 - 09:00   **Silvia Morbelli** (Turin, Italy): PET Imaging in Anti-Amyloid Therapies

09:00 - 09:30   **Philipp Scheltens** (Amsterdam, Netherlands): MR Imaging of ARIAs

Educational Objectives:
1. Learn which anti-amyloid drugs are currently expected to enter the clinical field
2. Understand the role of amyloid and tau PET imaging in the context of anti-amyloid drug prescription
3. Get an overview on the use of MRI to detect/exclude ARIAs under anti-amyloid treatment

Summary:
It is expected that, soon, anti-amyloid antibodies will be approved to treat early Alzheimer's disease. Amyloid PET imaging is able to establish the presence of the drug target and to measure biological drug efficacy. Tau PET imaging is likewise used at least for one drug candidate to further qualify drug treatment candidates. During the treatment period, repeated MRIs are required to detect/exclude side effects within the brain. This symposium jointly organized with the European Academy of Neurology (EAN) will provide an overview on this most interesting new development in the field of Alzheimer care.

Key Words:
Anti-amyloid; lecanemab; donanemab; amyloid PET; ARIA